Featuring perspectives from Dr Stephen V Liu and Dr Charles Rudin, including the following topics: 

• Introduction (0:00)
• Case 1: Adjuvant Systemic Therapy? (1:15)
• Case 2: Lambert-Eaton Syndrome and Other Paraneoplastic Syndromes (4:16)
• Case 3: Small Cell Transformation of EGFR-Mutant Non-Small Cell Lung Cancer (9:54)
• Case 4: Trilaciclib in Extensive-Stage Disease (13:50)
• Comments: ASCO and Other Recent Datasets (18:05)
• Case 5: Short Disease-Free-Interval with Brain Metastases After Chemoradiation Therapy/Durvalumab … Lurbinectedin? (39:34)
• Case 6: Tarlatamab After Rapid Disease Progression on Chemotherapy/Atezolizumab (44:33)
• Case 7: Immune Effector Cell-Associated Neurotoxicity Syndrome on Tarlatamab with Brain Metastases (48:54)
• Case 8: Bispecific T-Cell Engager with Lurbinectedin on Protocol (56:38)

CME information and select publications

Featuring an interview with Dr Shannon N Westin, including the following topics:

• Biomarker testing and utility in ovarian cancer (OC) (0:00)
• Selection of a PARP inhibitor for the treatment of OC (9:18)
• Addition of immunotherapy to up-front treatment of OC (15:50)
• Utility of minimal residual disease and circulating tumor DNA assays in OC (17:10)
• Selection of treatment for recurrent OC (21:46)
• Clinical decision-making involved with PARP inhibitors for endometrial cancer (EC) (28:22)
• Adjuvant therapy for EC (32:28)
• Utility of lenvatinib/pembrolizumab in EC (35:08)
• Clinical findings supporting the potential use of selinexor for EC (39:42)
• Key findings involving trastuzumab deruxtecan (T-DXd) for HER2-positive gynecologic cancers (43:22)
• Management of adverse effects associated with T-DXd (49:49)

CME information and select publications

Featuring an interview with Dr Jacob Sands, including the following topics:

• TROPION-Lung05 Trial: Datopotamab Deruxtecan for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations (0:00)
  • Sands J et al. Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: Results from the phase II TROPION-Lung05 study. J Clin Oncol 2025;43(10):1254-65. Abstract
• Phase III Randomized Clinical Trial Data with TROP2-Targeting Antibody-Drug Conjugates for Previously Treated Advanced NSCLC (6:52)
  • Ahn M-J et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: The randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol 2025;43(3):260-72. Abstract
  • Reinmuth N et al. Longer follow-up for survival and safety from the EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel in patients (pts) with metastatic non-small cell lung cancer (mNSCLC). ASCO 2025;Abstract 8599.
  • Paz-Ares LG et al. Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1 inhibitors (IO): Primary results from the phase 3 EVOKE-01 study. ASCO 2024;Abstract LBA8500.
• Evaluating TROP2 Expression Levels Through Normalized Membrane Ratio of TROP2 in the TROPION-Lung01 Trial (12:26)
  • Garassino MC et al. Normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-Lung01. WCLC 2024;Abstract PL02.11.

CME information and select publications

Featuring perspectives from Dr Natalie S Callander and Dr Sagar Lonial, including the following topics: 

• Introduction: Multiple Myeloma — 2005 to 2025 (0:00)
• Questions from the Beginning (7:53)
• Choosing Options (13:54)
• Clinical Trials (18:03)
• Neuropathy (23:55)
• Chimeric Antigen Receptor (CAR) T-Cell Therapy (28:40)
• Bispecific Antibodies (35:18)
• Antibody-Drug Conjugates (43:08)
• Interacting with the Oncology Team (51:47)
• Other Questions (57:30)

Educational and presenter information

Featuring an interview with Dr Jorge Cortes, including the following topics:

• Overview of common molecular profiles in newly diagnosed acute myeloid leukemia (AML) (0:00)
• Clinical presentation of AML with a FLT3 mutation; implications of clinical data from the Phase III RATIFY trial of the FLT3 inhibitor midostaurin (5:38)
• Potential incorporation of a FLT3 inhibitor with azacitidine/venetoclax for transplant-ineligible patients with FLT3-mutant AML (10:32)
• Clinical benefit with quizartinib for patients with FLT3-like genetic profile; selection of FLT3 inhibitor as a component of initial therapy for individuals with AML with a FLT3-ITD mutation (14:04)
• Overview of FDA-approved IDH inhibitors enasidenib, ivosidenib and olutasidenib; differentiation syndrome as a class effect of IDH inhibitors in AML (20:31)
• Case: A woman in her late 60s with newly diagnosed AML with FLT3-ITD and NPM1 mutations receives 7+3 chemotherapy in combination with quizartinib (31:07)
• Case: A patient in their late 70s with multiple comorbidities and newly diagnosed IDH1-mutant AML (37:53)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Jorge Cortes, including the following topics:

• Oncology Today with Dr Neil Love: Perspectives on New Datasets in FLT3- and IDH1/2-Mutant Acute Myeloid Leukemia — Dr Cortes (0:00)

CME information and select publications

Featuring perspectives from Dr Benjamin Levy, including the following topics:

• Introduction: The Boards (0:00)
• Immune Checkpoint Inhibition for Localized Non-Small Cell Lung Cancer (NSCLC) (11:43)
• Immunotherapy for Metastatic NSCLC (24:41)
• Antibody-Drug Conjugates (33:46)
• Novel Bispecific Antibodies (42:08)
• Journal Club with Dr Levy (51:28)

CME information and select publications

Featuring perspectives from Prof Xavier Leleu and Dr Peter Voorhees, including the following topics:

• Introduction: Myeloma Time Capsule (0:00)
• Smoldering Myeloma (7:21)
• Autologous Stem Cell Transplant (ASCT) Eligible Patients (13:05)
• ASCT Ineligible Patients (32:18)
• Subcutaneous Anti-CD38 Antibodies (47:24)
• Special Considerations (54:27)

CME information and select publications

Optimizing the Selection of First-Line Therapy for Patients with Multiple Myeloma | Faculty Presentation — Peter Voorhees, MD

CME information and select publications

Featuring an interview with Dr Erika Hamilton, including the following topics:

• Optimal selection and sequencing of available antibody-drug conjugates for HR-positive metastatic breast cancer (0:00)
  • Bardia A et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-Breast01. J Clin Oncol 2025;43(3):285-96. Abstract 
  • Pistilli B et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Final overall survival from the Phase III TROPION-Breast01 trial. ESMO Virtual Plenary 2025;Abstract VP1-2025.
• First-line use of sacituzumab govitecan in combination with pembrolizumab for advanced triple-negative breast cancer (8:02)
  • Tolaney SM et al. Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. ASCO 2025;Abstract LBA109.
• Ongoing trials evaluating datopotamab deruxtecan in earlier lines of therapy (12:06)
  • Dent RA et al. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol 2023;19(35):2349-59. Abstract
  • McArthur HL et al. TROPION-Breast04: A randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer. Ther Adv Med Oncol 2025;17:17588359251316176. Abstract
  • Bardia A et al. TROPION-Breast03: A randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol 2024;16:17588359241248336. Abstract
  • Schmid P et al. TROPION-Breast05: A randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer. Ther Adv Med Oncol 2025;17:17588359251327992. Abstract
• Available data with and ongoing trials of sacituzumab tirumotecan for HR-positive, HER2-negative and triple-negative breast cancer (16:53)
  • Yin Y et al. Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study. ASCO 2025;Abstract 1019.
  • Xu B et al. Sacituzumab tirumotecan in patients with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the Phase III Opti-TROP-Breast01 study. ASCO 2024;Abstract 104.
  • Yin Y et al. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: A randomized phase 3 trial. Nat Med 2025;31(6):1969-1975. Abstract
  • Garrido-Castro AC et al. SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic HR+/HER2-negative breast cancer. ASCO 2024;Abstract LBA1004.

CME information and select publications